M. Suárez-Calvet has served as a consultant and at advisory boards for Roche Diagnostics International Ltd. and Grifols S.L.; has given lectures in symposia sponsored by Roche Diagnostics, S.L.U., and Roche Farma, S.A.; was granted with a project funded by Roche Diagnostics International Ltd.; and receives funding from the European Research Council (ERC) under the European Union's Horizon 2020 Research and Innovation Programme (grant agreement 948677), Project “PI19/00155,” funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union, from a fellowship from “la Caixa” Foundation (ID 100010434), and from the European Union's Horizon 2020 Research and Innovation Programme under the Marie Skłodowska-Curie grant agreement 847648. J.D. Gispert receives research funding from Roche Diagnostics and GE Healthcare and has given lectures at symposia sponsored by Biogen and Philips. G. Salvadó has received speaker fees from Springer, GE Healthcare, Biogen, Esteve, and Adium; and serves on the advisory board of Johnson & Johnson. H. Zetterberg has served at scientific advisory boards and/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZPath, Annexon, Apellis, Artery Therapeutics, AZTherapies, Cognito Therapeutics, CogRx, Denali, Eisai, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave; has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure, Biogen, and Roche; is a cofounder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program, outside the work presented in this article; is a Wallenberg Scholar and a Distinguished Professor at the Swedish Research Council; and was supported by grants from the Swedish Research Council (2023-00356, 2022-01018, and 2019-02397); the European Union's Horizon Europe Research and Innovation Programme under grant agreement 101053962; Swedish State Support for Clinical Research (ALFGBG-71320); the Alzheimer Drug Discovery Foundation (ADDF), United States (201809-2016862); the AD Strategic Fund and the Alzheimer's Association (ADSF-21-831376-C, ADSF-21-831381-C, ADSF-21-831377-C, and ADSF-24-1284328-C); the European Partnership on Metrology, co-financed from the European Union's Horizon Europe Research and Innovation Programme and by the participating states (NEuroBioStand, 22HLT07); the Bluefield Project; Cure Alzheimer's Fund; the Olav Thon Foundation; the Erling-Persson Family Foundation; Familjen Rönströms Stiftelse, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (FO2022-0270); the European Union's Horizon 2020 Research and Innovation Programme under the Marie Skłodowska-Curie grant agreement 860197 (MIRIADE); the European Union Joint Programme—Neurodegenerative Disease Research (JPND2021-00694); the National Institute for Health and Care Research University College London Hospitals Biomedical Research Centre; the UK Dementia Research Institute at UCL (UKDRI-1003); and an anonymous donor. K. Blennow has served as a consultant and at advisory boards for Abbvie, AC Immune, ALZPath, AriBio, Beckman-Coulter, BioArctic, Biogen, Eisai, Lilly, Moleac Pte. Ltd., Neurimmune, Novartis, Ono Pharma, Prothena, Quanterix, Roche Diagnostics, Sunbird Bio, Sanofi, and Siemens Healthineers; has served at data monitoring committees for Julius Clinical and Novartis; has given lectures, produced educational materials, and participated in educational programs for AC Immune, Biogen, Celdara Medical, Eisai, and Roche Diagnostics; is a cofounder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program, outside the work presented in this article; and was supported by the Swedish Research Council (2017-00915 and 2022-00732); the Swedish Alzheimer Foundation (AF-930351, AF-939721, and AF-968270); Hjärnfonden, Sweden (FO2017-0243 and ALZ2022-0006); the Swedish state under the agreement between the Swedish government and the County Councils, the ALF agreement (ALFGBG-715986 and ALFGBG-965240); the European Union Joint Program for Neurodegenerative Disorders (JPND2019-466-236); the Alzheimer's Association 2021 Zenith Award (ZEN-21-848495); and the Alzheimer's Association 2022–2025 Grant (SG-23-1038904 QC). O. Grau-Rivera was supported by the Spanish Ministry of Science and Innovation–State Research Agency (IJC2020-043417-I/MCIN/AEI/10.13039/501100011033) and the European Union laquoNextGenerationEUraquo/PRTR; and receives research funding from Roche Pharma. G. Sánchez-Benavides was supported by the Agencia Estatal de Investigación AEI/10.13039/501100011033 through the project PID2020-119556RA-I00 and Instituto de Salud Carlos III (ISCIII) through the project CP23/00039 (Miguel Servet contract), co-funded by the European Union (FSE+) and worked as a consultant for Roche Farma, S.A. All other authors report no disclosures relevant to the manuscript. Go to Neurology.org/N for full disclosures.
PubMed
